Chinook Therapeutics, Inc. (KDNY) financial statements (2022 and earlier)

Company profile

Business Address 400 FAIRVIEW AVENUE NORTH, SUITE 900
SEATTLE, WA 98109
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments286,837247,372213,602266,439326,103347,432415,654
Cash and cash equivalents181,724187,75059,624126,310157,61474,932150,456
Short-term investments105,11359,622153,978140,129168,489272,500265,198
Receivables10,06126234212,0379891,1384,846
Other undisclosed current assets3,7416,4473,9584,50023,0396,1944,004
Total current assets:300,639254,081217,902282,976350,131354,764424,504
Noncurrent Assets
Operating lease, right-of-use asset55,38555,67321,110
Property, plant and equipment18,93520,62624,68829,15731,08526,3843,986
Long-term investments and receivables76,4203,000 11,43423,61414,47415,391
Long-term investments76,4203,000 11,43423,61414,47415,391
Intangible assets, net (including goodwill)62,67689,43227,14533,46939,83035,48537,869
Goodwill11722,4418,1678,3348,7237,6588,469
Intangible assets, net (excluding goodwill)62,55966,99118,97825,13531,10727,82729,400
Restricted cash and investments2,0741,750468468468468 
Other noncurrent assets6,4744,440   71775
Other undisclosed noncurrent assets41,200    6,319 
Total noncurrent assets:263,164174,92173,41174,52894,99783,84757,321
TOTAL ASSETS:563,803429,002291,313357,504445,128438,611481,825
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,3754,2077,6749,3629,19810,35610,498
Accounts payable8,5803,9954141,4571,1502,2065,086
Accrued liabilities3402123,5833,2862,7283,1162,647
Employee-related liabilities6,455 3,6774,6195,3204,2282,765
Taxes payable     806 
Deferred revenue 956,950
Debt  1,803    
Deferred rent credit   653
Due to related parties 9     
Business combination, contingent consideration, liability    6,829  
Deferred revenue and credits14,92315,05215,046
Contract with customer, liability16,000
Other undisclosed current liabilities24,71018,4985,1744,50210,4515,2245,522
Total current liabilities:40,08522,80921,60130,51741,40130,63231,066
Noncurrent Liabilities
Long-term debt and lease obligation39,58938,70931,636    
Operating lease, liability39,58938,70931,636
Liabilities, other than long-term debt5,89519,082168,954191,676166,254180,759189,137
Deferred revenue and credits158,139169,749178,037
Deferred revenue  166,963
Contract with customer, liability172,671
Deferred rent credit   11,063
Deferred tax liabilities, net6,1046,5385,8697,350
Deferred income tax liabilities73516,377 
Other liabilities 9059408408181,109 
Business combination, contingent consideration, liability5,1601,8001,0519987594,0323,750
Other undisclosed noncurrent liabilities24,59113,7803,527    
Total noncurrent liabilities:70,07571,571204,117191,676166,254180,759189,137
Total liabilities:110,16094,380225,718222,193207,655211,391220,203
Stockholders' equity
Stockholders' equity attributable to parent453,643334,62265,595135,311237,473227,220261,622
Common stock5488876
Additional paid in capital685,459463,436552,077538,895519,435420,897362,807
Accumulated other comprehensive income (loss)(55)114149401,893(1,684)(339)
Accumulated deficit(231,766)(128,829)(486,904)(404,532)(283,863)(192,000)(100,852)
Total stockholders' equity:453,643334,62265,595135,311237,473227,220261,622
TOTAL LIABILITIES AND EQUITY:563,803429,002291,313357,504445,128438,611481,825

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues51,62525,50017,25815,08717,23950,68172,979
Revenue, net17,23950,68172,979
Sublease income 25,500 
Gross profit:51,62525,50017,25815,08717,23950,68172,979
Operating expenses(121,659)(57,054)(107,400)(116,447)(123,692)(122,544)(86,543)
Other undisclosed operating loss(29,004)(24,673)     
Operating loss:(99,038)(56,227)(90,142)(101,360)(106,453)(71,863)(13,564)
Nonoperating income (expense)(170)3135,3585,2203,226(40)(161)
Investment income, nonoperating  5,4515,2843,444  
Other nonoperating income (expense)(170)313(93)(64)(218)(40)(161)
Interest and debt expense (15)     
Loss from continuing operations before equity method investments, income taxes:(99,208)(55,929)(84,784)(96,140)(103,227)(71,903)(13,725)
Loss from equity method investments(1,636)      
Other undisclosed income (loss) from continuing operations before income taxes (27,696)   2,219(25,583)
Loss from continuing operations before income taxes:(100,844)(83,625)(84,784)(96,140)(103,227)(69,684)(39,308)
Income tax expense (benefit)(2,093)2,0032,41278311,364(21,464)99
Net loss available to common stockholders, diluted:(102,937)(81,622)(82,372)(95,357)(91,863)(91,148)(39,209)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(102,937)(81,622)(82,372)(95,357)(91,863)(91,148)(39,209)
Other comprehensive income (loss)(66)18(526)(953)3,577(1,345)(339)
Comprehensive loss, net of tax, attributable to parent:(103,003)(81,604)(82,898)(96,310)(88,286)(92,493)(39,548)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: